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Bacopa monnieri (L.) Pennell (Scrophularia-
ceae) is one of the most important plants of Hindu
traditional medicine known as Ayurveda. The term
Ayurveda has its roots in ancient India and is trans-
lated as ìthe sacred knowledge of life.î Local inhab-
itants of India call the plant Brahmi. The name
Brahmi is not accidental, because it comes from the
word Brahma, which refers to one of the three main
gods of Hinduism. Giving a new local name derived
from one of the Hindu gods shows how valuable and
important B. monnieri is for the Indians (1-7). Raw
material from this plant has been used since several
centuries before Christ in the treatment of various
diseases (8-11). The B. monnieri herb was provided
to ease sleep and as an anti-anxiety agent (12).
Currently, the main reason for using preparations
from this plant is to improve memory and concen-
tration (13, 14). The mechanism of action of B. mon-
nieri supporting the normalization of memory
processes affects the reactions occurring in the
cholinergic system, which is responsible inter alia
for memory processes (15-19). Because of the bene-
ficial effects of the preparations produced from 
B. monnieri on human memory, it is also used in
addition to the treatment of neurodegenerative dis-
eases such as Parkinsonís disease and Alzheimerís
disease. The purpose of this work was to quantita-
tively determine the metals (Fe, Mg, and Zn) con-
tained in tablets and capsules made of B. monnieri
and in their shoot cultures. These elements were
chosen for the experiment because of their pro-
health activity close to B. monnieri profile of activi-
ty. It was also decided to analyze the same metals
after extracting preparations to obtain artificial
digestive juices, to assess their suitability for the
supplementation of the human body in the analyzed
bioelements. Metals were determined using the
atomic absorption spectrometry method (flame tech-
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nique) in the obtained extracts after the incubation
of products containing B. monnieri in the artificial
digestive juices (gastric and intestinal). In the experi-
ment, organic compounds such as phenolic com-
pounds with antioxidant activity and bacoside A (the
main active substance of this plant), which enhances
the blood flow through the brain, were determined
using the high-performance liquid chromatography
(RP-HPLC) method (4, 16). In addition, the above-
mentioned elements and organic compounds were
determined in the methanol extracts from the 
B. monnieri preparations and biomass.
Furthermore, it was determined which form
(capsules or tablets) of preparations made from 
B. monnieri after extraction into the artificial diges-
tive juices (gastric and intestinal) and methanol
released the largest amount of bioelements as well
as the tested organic compounds (phenolic com-
pounds and bacoside A). 
MATERIALS AND METHODS
Materials
The study involved the use of commercial
dietary supplements in the form of tablets and cap-
sules of B. monnieri and the shoots from the in vitro
cultures of this plant (Table 1). The in vitro cultures
were established from the commercially available in
vitro cultures of B. monnieri from IVPLANT (19).
Representative samples of the B. monnieri in vitro
cultures were deposited at the Department of
Pharmaceutical Botany, Jagiellonian University
Collegium Medicum, KrakÛw, Poland. B. monnieri
shoots were identified by the Department of
Pharmaceutical Botany, Pharmacy College.
Reagents and standards
Standards of organic compounds, i.e., p-
hydroxybenzoic, ferulic, and isoferulic acids were
obtained from Fluka (Chemie AG, Germany), and
those of caffeic, chlorogenic, neochlorogenic, iso-
chlorogenic, protocatechuic acid, cynaroside, trifo-
lin, luteolin, and bacoside A were from Sigma-
Aldrich (St. Louis, USA). HPLC-grade methanol,
acetic acid, and acetonitrile were purchased from
Merck (Darmstadt, Germany). MgCl2 was obtained
from Chempur (KrakÛw, Poland); NaCl, KCl, and
NaHCO3 were purchased from PPH Galfarm
(KrakÛw, Poland); pepsin and bile salts were bought
from BTL (£Ûdü, Poland); CaCl2 was purchased
from Pharma Zentrale GmbH (Germany); pancreat-
ic extract, HCl, KCl, concentrated HNO3, Supra-
purÆ, and H2O2 were obtained from Merck (Darm-
stadt, Germany); and C6H8O7, ZnSO4, KHCO3,
Na2HPO4, K2HPO4, and NaOH were bought from
Polish Company of Chemistry (Gliwice, Poland).
Water (four times distilled) with a conductivity of
less than 1 µS cm-1 was obtained using an S2-97A2
distillation apparatus (ChemLand, Stargard Szcze-
cin, Poland).
The Fe(III), Mg(II), and Zn(II) ion standards at
the concentration of 1 g/L were purchased at the
Regional Office of Measures in £Ûdü, Poland.
Analysis of metals in Bacopa monnieri prepara-
tions 
To determine the content of metals (Fe, Mg,
and Zn) in the B. monnieri preparations, the samples
were subjected to mineralization. For this purpose,
the samples of the preparations were prepared in the
amount corresponding to the daily maximum dose
(Bacopa A, 3.1 g; Bacopa B, 0.8 g; Bacopa C, 1.6 g;
Bacopa D, 0.5 g; and Bacopa E, 0.5 g).
The weighed samples were transferred to
Teflon tubes to which 2 mL of hydrogen peroxide
and 4 mL of concentrated nitric acid solution were
added. The mineralization of the B. monnieri prepa-
rations and biomass was performed in the Magnum
II microwave mineralizator, ERTEC. Mineralization
was conducted for 40 min in three magnetron work
cycles of 15 min at 70% power, 15 min at 80%
power, and 10 min at 100% power at 290OC. The
metals in the solutions obtained after the mineraliza-
tion were determined using atomic absorption spec-
Table 1. Dietary supplements containing B. monnieri, which were used to determine the solidity of metals after extraction into the artifi-
cial digestive juices.
Preparation Form Expiration date
Bacopa A Tablets 11.2017
Bacopa B Tablets 06.2018
Bacopa C Capsules 10.2018
Bacopa D Shoot cultures 12.2019
Bacopa E Shoot cultures with the addition of magnesium sulfate 12.2019
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trometry (flame technique) (iCE 3500 spectrometer,
Thermo Scientific, UK). The solutions after miner-
alization were transferred to a quartz steamer and
evaporated on a heating plate at 150OC to remove
excess reagents. The residue was quantitatively
transferred to a 10-mL graduated flask using four
times distilled water. The Fe, Mg, and Zn concen-
trations were determined using atomic absorption
spectrometry (F-AAS method). An atomic absorp-
tion spectrometer from Thermo Scientific, Model
iCE 3500 (UK), was used for all of the measure-
ments. Each sample was analyzed in three inde-
pendent replicates, and the results are presented as
mean values (Table 2). 
Analysis of metals and organic compounds in
extracts obtained from preparations and cultures
of Bacopa monnieri
Artificial digestive juices were prepared
according to the methodology previously presented
by Rojowski et al. 2017 (20).
Extracts from the preparations from B. mon-
nieri used for the studies of the release of metals,
phenolic compounds, and bacosides into the artifi-
cial digestive juices (20-22) were obtained as a
result of the in vitro digestion process performed in
the Gastroel-2014 prototype apparatus and the
methanol extraction in the percolator (19, 23). We
weighed 0.5 g of the shoots from the shoot cultures
and a certain amount of the preparations (tablets and
capsules) corresponding to the maximum daily dose
recommended for the studied supplements contain-
ing B. monnieri. The weighed material was trans-
ferred to 100-mL Erlenmeyer flasks, moistened with
a 2-mL solution of artificial saliva; then, 20 mL of
gastric juice was added into the flasks. The closed
flasks were placed in the Gastroel-2014 apparatus,
in which the digestive process was conducted. The
process was performed for 30 and 60 min, respec-
tively. The obtained extracts were filtered using
paper filters and membrane syringe filters. The col-
lected filtrates were used to analyze the concentra-
tions of metals and phenolic compounds. The
remaining material was re-transferred to Erlenmeyer
flasks, and 20 mL of intestinal juice was added. The
digestion process was conducted for 150 min. After
150 min, the contents were re-filtered to obtain a
clear solution in which, analogically to the digestion
in the gastric juice, the content of metals and organ-
ic compounds was examined. 
Bacopa monnieri methanolic extracts preparation
The powdered shoots (0.5 g) from the in vitro
shoot cultures of B. monnieri and the same amounts
of the preparations (tablets and capsules) were sub-
jected to extraction with methanol (10 portions of
100 mL) in a percolator. The methanolic extract was
left at room temperature to dry. The residue was
quantitatively dissolved in methanol, filtered
through Millipore MillexñGP, 0.22 µm, and was
subjected to an RP-HPLC analysis. 
RP-HPLC analysis of organic compounds 
The biomass and preparation extracts contain-
ing B. monnieri obtained by extraction with the
digestive juices and methanol were analyzed for the
content of phenolic compounds by using the RP-
HPLC method using a Merck-Hitachi liquid chro-
matograph (LaChrom Elite) equipped with a DAD
detector L-2455 and a PurospherÆ RP-18e (250 mm
Table 2. Fe, Mg, and Zn in the selected formulations containing B. monnieri.
Preparation
Metals content in the preparations containing B. monnieri [mg/100 g ± SD]
Fe Mg Zn
Bacopa A 1.49 ± 0.06 a 111.72 ± 14.00 a 0.16 ± 0.01 a
Bacopa B 13.85 ± 1.74 a,b 49.16 ± 6.15 a,b 0.17 ± 0.02 b
Bacopa C 18.92 ± 0.05 a,b,c 367.51 ± 5.01 a,b,c 1.88 ± 0.01 a,b,c
Bacopa D 32.85 ± 4.76 a,b,c 155.08 ± 30.91 a,b,c,d 1.96 ± 0.63 a,b,d
Bacopa E 31.73 ± 2.25 a,b,c 282.87 ± 14.12 a,b,c,d 16.41 ± 0.11 a,c,d
Parameters of method
Range [mg/L] 1-6 0.1-0.5 1-4
Precison 0.03 0.04 0.01
Repeatability [%] 93.21 96.36 94.50
Data are presented as mean ± SD (standard deviation); n = 3. Tukey-Kramer test was used to reveal the differences between paired groups
of phenolic compounds in rows, the same letters (a, b, c, d) are marked for the content whose differences are statistically significant (for p
values < 0.05) (GraphPad InStat)
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◊ 4 mm/5 mm) column. These analyses were con-
ducted according to the methodology developed by
Su≥kowska-Ziaja (24). The analyses were performed
at 25OC, with a mobile phase consisting of A:
methanol and B: methanol: 0.5% acetic acid, 1 : 4
(v/v). The gradient was as follows: 100% B for 0ñ20
min, 100%ñ80% B for 20ñ35 min, 80%ñ60% B for
35ñ55 min, 60%ñ0% B for 55ñ70 min, 0% B for
70ñ75 min, 0%ñ100% B for 75ñ80 min, and 100%
B for 80ñ90 min at a flow rate 1 mL/min at λ = 254
nm (phenolic acids and catechins) and λ = 370 nm
(flavonoids). The phenolic compounds were quanti-
fied by measuring the peak area with reference to
the standard curve derived from five concentrations
(0.03ñ0.50 mg/mL). 
Similar to the analysis of phenolic compounds,
extracts from the biomass and from preparations
containing B. monnieri obtained as a result of extrac-
tion with digestive juices and methanol were ana-
lyzed for the content of bacosides by using the RP-
HPLC method. The RP-HPLC analyses were con-
ducted according to the method described elsewhere
(25). Analyses were performed at 25OC, with a
mobile phase consisting of A: acetonitrile, B: ace-
tonitrile: 0.5% phosphoric acid (0.01 mol/L) 35 : 65
(v/v); gradient elution: A (0 : 100%), B (100% : 0)
at a flow rate of 1 mL/min, λ = 205 nm.
Quantification was performed by the measurement
of the peak area with reference to the standard of
bacoside A (bacoside A3, bacopaside II, bacopaside
X, and bacopasaponin C) curve derived from five
concentrations (0.1875 to 3 mg/mL). A quantitative
analysis of the organic compounds was performed
using a calibration curve assuming the linear size of
the area under the peak and the concentration of the
reference standard. The results were expressed in
milligrams per 100 grams of dry weight (d.w.).
Statistical analysis
The statistical analysis of the data was per-
formed using one-way ANOVA with the Tukey-
Kramer post-hoc multiple-comparison test. The
value p < 0.05 was accepted as the level of statisti-
cal significance.
RESULTS AND DISCUSSION
The F-AAS method, which is characterized by
high sensitivity, repeatability, and precision, was
used to determine the concentration of Zn, Mg, and
Fe in the preparations containing B. monnieri (pow-
dered shoots, tablets, and capsules) and its extracts
converted into the artificial digestive juices and
methanol. The considered conditions and optimiza-
tion of the analytical method allowed for an effec-
tive determination of the abovementioned elements
in the tested preparations and extracts. 
The Zn content in the tested preparations
ranged from 0.16 mg/100 g of the preparation to
16.41 mg/100 g of the preparation. The highest con-
tent of Zn was determined in the biomass obtained
from the in vitro cultures enriched with the addition
of MgSO4 (16.41 mg/100 g of the preparation).
However, the smallest content of this element was
determined in a commercial preparation available in
the form of compressed tablets: 0.16 mg/100 g of the
preparation (Table 2).
In the case of the preparations in the form of
tablets, very similar amounts were determined: 0.16
and 0.17 mg/100 g of the preparation. 
To estimate the actual amounts of this element
available to the human body, extraction was per-
formed into the artificial digestive juices (using the
Gastroel-2014 apparatus). Extraction was conducted
under conditions imitating those prevailing in the
Figure 1. Zinc content (milligrams per 100 g of the preparation) after extraction into a) gastric juice after 30 and 60 min, and b) intestinal
juice after 30 and 60 min of incubation in gastric juice
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human body (temperature 37OC and movements imi-
tating peristalsis in the human gastrointestinal tract). 
Based on the AAS method used for extraction into
the artificial digestive juices, Zn was found to have
been better extracted from the biomass from the in
vitro shoot cultures than from the commercial prepa-
rations in the form of tablets or capsules. The quan-
tities of Zn released into the artificial digestive
juices were in the range of 0.07 to 6.86 mg/100 g of
the preparation (Figs. 1a and b). The largest amount
of zinc determined in the artificial gastric juice was
in the range of 0.10 to 6.86 mg/100 g of the prepa-
ration, after 30 min of incubation. In contrast, in the
artificial intestinal juice, these quantities were sig-
nificantly lower, irrespective of the incubation time.
In the case of formulations A and B, no extraction
into the intestinal juice was observed, whereas for
preparations C, D, and E, the amounts determined
ranged from 0.07 to 1.41 mg/100 g of the prepara-
tion. The largest amount was released into the gas-
tric juice after 30 min of incubation (Figs. 1a and b)
from preparation E, i.e., from the in vitro culture bio-
mass, and was 6.86 mg/100 g of the preparation.
Zinc was released more efficiently from the prepa-
rations containing B. monnieri in capsules than from
the commercial preparations in the form of tablets.
From the results obtained for the magnesium analy-
sis, we found that the content of this element in the
preparations ranged from 49.16 mg/100 g of the
preparation to 367.51 mg/100 g of the preparation.
This element was released into the artificial diges-
tive juices in amounts ranging from 22.92 mg/100 g
Figure 2. Magnesium content (milligrams per 100 g of the preparation) after extraction into a) gastric juice after 30 and 60 min, and b)
intestinal juice after 30 and 60 min of incubation in gastric juice
Figure 3. Iron content (milligrams per 100 g of the preparation) after extraction into a) gastric juice after 30 and 60 min, and b) intestinal
juice after 30 and 60 min of incubation in gastric juice
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Table 3. Content of phenolic compounds released into the artificial digestive juices from the analyzed preparations of B. monnieri.
Artificial juice 
Artificial stomach juice Artificial intestinal juice
(mg/100 g of the preparation) (mg/ 100 g of the preparation) 
Time [min] 30 60 150 150 Preparation
(after 1 min incubation (after incubation 
Preparation in artificial saliva) in artificial stomach juice)   
Extract to artificial Methanolic extract
digestive juice   (control)
Protocatechuic acid
Bacopa A 0.10 ± 0.00 a 0.10 ± 0.01 a 0.10 ± 0.00 a 0.13 ± 0.00 a 0.56 ± 0.01 a
Bacopa B 0.45 ± 0.03 a,b 0.43 ± 0.01 a,b 0.34 ± 0.01 a,b 0.34 ± 0.03 a,b 0.40 ± 0.00 a,b
Bacopa C 0.40 ± 0.03 a,b 0.33 ± 0.00 a,b 0.16 ± 0.01 a,b 0.17 ± 0.00 a,b 3.00 ± 0.01 a,b
Bacopa D - - - - -
Bacopa E - - - - -  
p-Hydroxybenzoic acid
Bacopa A 0.03 ± 0.00 a 0.03 ± 0.00 a - - 0.14 ± 0.01 a
Bacopa B 0.10 ± 0.00 a,b 0.12 ± 0.00 a,b - - 0.16 ± 0.02 b
Bacopa C 0.27 ± 0.02 a,b 0.22 ± 0.02 a,b 0.15 ± 0.03 0.16 ± 0.02 4.05 ± 0.12 a,b
Bacopa D - - - - -
Bacopa E - - - - -
Neochlorogenic acid
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C - - - - -
Bacopa D 0.80 ± 0.03 0.96 ± 0.07 - - 7.42 ± 0.06
Bacopa E 1.11 ± 0.16 0.86 ± 0.02 6.94 ± 0.65
Chlorogenic acid
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C - - - - -
Bacopa D 4.43 ± 0.66 5.25 ± 0.31 - - 15.04 ± 0.75
Bacopa E 1.96 ± 0.08 2.34 ± 0.4 - - 73.31 ± 0.71
Isochlorogenic acid
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C - - - - -
Bacopa D 35.88 ± 3.51 45.10 ± 6.24 - - 181.16 ± 1.29
Bacopa E 32.03 ± 1.81 34.49 ± 4.20 - - 864.79 ± 17.0
Caffeic acid
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C - - - - -
Bacopa D 2.86 ± 0.22 3.13 ± 0.38 - - 3.50 ± 0.03
Bacopa E 2.84 ± 0.14 2.72 ± 0.18 - - 6.60 ± 0.14
Ferulic acid
Bacopa A - - - - -
Bacopa B - - - - -
Table 3. Continue.
Artificial juice 
Artificial stomach juice Artificial intestinal juice
(mg/100 g of the preparation) (mg/ 100 g of the preparation) 
Time [min] 30 60 150 150 Preparation
(after 1 min incubation (after incubation 
Preparation in artificial saliva) in artificial stomach juice)   
Extract to artificial Methanolic extract
digestive juice   (control)
Bacopa C - - - - -
Bacopa D 1.96 ± 0.08 2.7 ± 0.03 - - 226.76 ± 0.71
Bacopa E 2.66 ± 0.16 2.30 ± 0.67 0.30 ± 0.03 0.13 ± 0.00 109.65 ± 1.75
Isoferulic acid
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C - - - - -
Bacopa D 5.39 ± 0.09 5.26 ± 0.22 - - 20.58 ± 0.35
Bacopa E 5.30 ± 0.21 5.41 ± 0.17 - - 10.76 ± 0.39
Cynaroside
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C 3.76 ± 0.03 3.82 ± 0.08 3.68 ± 0.01 3.73 ± 0.11 7.69 ± 0.27
Bacopa D - - - - -
Bacopa E - - - - -
Trifolin
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C 3.62 ± 0.74 3.60 ± 0.49 0.99 ± 0.01 1.16 ± 0.12 -
Bacopa D - - - - -
Bacopa E - - - - -
Luteolin
Bacopa A - - - - -
Bacopa B - - - - -
Bacopa C 0.21 ± 0.01 0.21 ± 0.01 0.17 ± 0.00 0.17 ± 0.00 2.97 ± 0.03
Bacopa D - - - - -
Bacopa E - - - - -
Bacoside A
Bacopa A - - - - 29.42 ± 1.60 a
Bacopa B - - - - 3.81 ± 0.31 a,b
Bacopa C - - - - 1.10 ± 0.001 a,c
Bacopa D - - - - 91.29 ± 0.11 a,b,c,d
Bacopa E - - - - 327.4 ± 22.55 a,b,c.d
Data are presented as the mean ± standard deviation (SD); n=3 repetitions; TukeyñKramer test was used to reveal the differences between
paired groups of phenolic compounds in columns, the same letters (a, b, c, d) are marked for the content whose differences are statistical-
ly significant (for p values <0.05) (GraphPad InStat)
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of the preparation to 228.19 mg/100 g of the prepa-
ration for gastric juice and from 8.09 mg/100 g of
the preparation to 37.59 mg/100 g in the intestinal
juice. In the case of Mg, the incubation time in the
artificial gastric juice affected the amount of ele-
ment released. Increasing the incubation time from
30 min to 60 min increased the extraction efficien-
cy, for which the best result was recorded for for-
mulation C in the form of capsules: 228.19 mg/100
g of the preparation (Figs. 2a and b). In turn, the Fe
content in the analyzed preparations ranged from
1.49 mg/100 g of the preparation (Bacopa A) to
32.85 mg/100 g of the preparation (Bacopa D). The
analysis of the obtained extracts from the artificial
digestive juices indicated that this element was the
most effectively released into the gastric juice in the
amounts ranging from 0.28 mg/100 g of the prepa-
ration to 7.81 mg/100 g of the preparation. Further,
in this case, the effect of the time of incubation in
the digestive juices on the amount of element
released into them was demonstrated. The best
results were recorded for the incubation time of 60
min for the analysis of the biomass derived from the
B. monnieri (Bacopa D) shoot cultures (5.76 mg/100
g of the preparation) and shoot cultures supplemented
with MgSO4 (Bacopa E) (7.81 mg/100 g of the prepa-
ration). However, the smallest amount of iron was
extracted into the artificial gastric juice from a com-
mercial preparation in the tablet form (Bacopa A)
(0.28 mg/100 g of the preparation) (Figs. 3a and b). 
The artificial digestive juices did not cause the
breakdown of the B. monnieri tablets even after the
maximum incubation time, i.e., 60 min in the artifi-
cial gastric juice and 150 min in the artificial intes-
tinal juice. During the experiment, a gel layer pre-
venting the penetration of liquids into the interior of
the tablet and the consequent disintegration of the
tablet was observed on the surface of the tablets.
Thus, small amounts of metals extracted into the
artificial digestive juices were found, which resulted
in the lack of the possibility of supplementing their
deficiencies (Fe, Mg, and Zn) in the human body by
using the B. monnieri preparations in the form of
tablets. 
Extracts into the digestive juices obtained dur-
ing the tests using the Gastroel-2014 apparatus
were also subjected to a qualitativeñquantitative
analysis of the content of organic compounds.
Thus, phenolic compounds such as protocatechuic
acid, p-hydroxybenzoic acid, neochlorogenic acid,
chlorogenic acid, isochlorogenic acid, caffeic acid,
ferulic acid, isoferulic acid, cynaroside, trifolin,
luteolin, and bacoside A were found in methanol
extracts and the artificial digestive juices (Table 3).
The commercial B. monnieri formulations provided
a source of phenolic compounds, particularly proto-
catechuic acid, p-hydroxybenzoic acid, neochloro-
genic acid, and chlorogenic acid. These compounds
were most effectively released into the artificial
gastric juice. In addition, the effect of the extraction
time into the artificial digestive juices on the
amount of phenolic compounds was not observed.
Based on the available literature sources, it was
estimated that a daily dose of phenolic compounds
delivered to a man along with the daily diet should
range from 0.1 to 1.0 g. This range is broad and
determined by ingredients of the daily diet, includ-
ing their quantity and diversity (consumption of
fruit, vegetables, and/or tea) (26). Considering the
marked amounts of phenolic compounds released
from the B. monnieri preparations into the artificial
digestive juices, we concluded that these formula-
tions were a supplementary source of the daily diet
in these compounds, providing them from 0.03
mg/day (p-hydroxybenzoic acid) to 45 mg/day
(isochlorogenic acid). The presence of these pheno-
lic compounds in the obtained extracts confirmed
the antioxidant activity of the raw material and the
preparations obtained from it. The presence of
bacoside A was found only in the methanol extracts
(for Bacopa A, B, C, D, and E material), which
indicated that the aqueous extracts could not be the
source of this important metabolite (3). This under-
mined the legitimacy of using the B. monnieri raw
materials and extracts (i.e., aqueous extracts and
oral preparations). Because of the bioavailability of
bacosides, we had to use only alcohol extracts. In
addition, we showed that Bacopa A present in the
form of tablets (compressed lyophilisate A) did not
break down during the digestion process, thus fail-
ing to meet pharmacopoeial standards required for
this form of the drug (disintegration should occur
within 15 min) (21, 27).
CONCLUSION 
Based on the conducted studies, it was found
that medicinal substances from the commercial
preparations of B. monnieri were released into the
artificial digestive juices and thus, could be compo-
nents potentially available to the human body and be
a valuable source of phenolic compounds that sup-
plement their deficiency. In contrast, metals (Fe,
Mg, and Zn) were released into the artificial diges-
tive juices to a different degree, and their effective-
ness depended on the form in which the given prepa-
ration from B. monnieri occurred. Most effectively,
the elements were released from the biomass from
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the B. monnieri shoot cultures, and their amounts
allowed us to supplement the daily demand for these
bioelements. Because of the bioavailability of baco-
sides, only alcohol extracts of B. monnieri were
used. The conducted experiment showed that the
capsules, in comparison to tablets, met pharma-
copoeial standards. We also found it necessary to
use alcohol extracts from the dried raw material of
B. monnieri, to deliver bacoside A to the human
body.
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